Your browser doesn't support javascript.
loading
Borderline pulmonary hypertension associated with chronic hypercapnia in chronic pulmonary disease.
Zuoyou, Liu; Shiota, Satomi; Morio, Yoshiteru; Sugiyama, Ai; Sekiya, Mitsuaki; Iwakami, Shin-Ichiro; Ienaga, Hiroki; Fukuchi, Yoshinosuke; Takahashi, Kazuhisa.
Afiliación
  • Zuoyou L; Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo, Japan.
  • Shiota S; Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo, Japan. Electronic address: sshiota@juntendo.ac.jp.
  • Morio Y; Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo, Japan; Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Tokyo, Japan.
  • Sugiyama A; Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo, Japan.
  • Sekiya M; Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo, Japan; Saiseikai Kawaguchi General Hospital, Saitama, Japan.
  • Iwakami SI; Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo, Japan; Department of Respiratory Medicine, Juntendo University Shizuoka Hospital, Shizuoka, Japan.
  • Ienaga H; Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo, Japan; Department of Respiratory Medicine, Koshigaya Municipal Hospital, Saitama, Japan.
  • Fukuchi Y; Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo, Japan.
  • Takahashi K; Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo, Japan.
Respir Physiol Neurobiol ; 262: 20-25, 2019 04.
Article en En | MEDLINE | ID: mdl-30660859
Pulmonary hypertension (PH) due to lung diseases is classified as group 3 by the Dana Point classification. Given the basic pathophysiological conditions of group 3 lung diseases and the previously well-known concept of hypercapnic pulmonary vasoconstriction, chronic hypercapnia besides alveolar hypoxia might be another causative factor to increase mean pulmonary arterial pressure (PAm). Two hundred twenty-five subjects with chronic pulmonary diseases were assessed by a right heart catheterization and blood gas parameters. The subjects were classified into the following 4 groups: Hypercapnic Hypoxia (HCHX), Hypercapnic Normoxia (HCnx), Normocapnic Hypoxia (ncHX), and Normocapnic Normoxia (ncnx). Compared with ncnx, the HCHX, HCnx and ncHX groups all showed significantly higher PAm and met the criteria of borderline PH. Multiple regression analysis showed that PaCO2, as well as SaO2, was an independent variable for PAm. Given the poor prognosis with borderline PH, the elimination of excess pulmonary carbon dioxide in hypercapnia could be a considerable treatment strategy in chronic pulmonary disease.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Hipercapnia / Hipertensión Pulmonar Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Respir Physiol Neurobiol Año: 2019 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Países Bajos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Hipercapnia / Hipertensión Pulmonar Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Respir Physiol Neurobiol Año: 2019 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Países Bajos